<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00303251</url>
  </required_header>
  <id_info>
    <org_study_id>CTKI258A2105</org_study_id>
    <nct_id>NCT00303251</nct_id>
  </id_info>
  <brief_title>Safety of TKI258 in Advanced/Metastatic Melanoma Subjects</brief_title>
  <official_title>A Phase I/II Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of TKI258 (CHIR-258) in Patients With Locally Advanced or Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is an open-label, dose-escalating study to delineate the safety, pharmacokinetics&#xD;
      (PK), and pharmacodynamics (PD) of TKI258. Pharmacokinetics and pharmacodynamics will be&#xD;
      performed on all subjects. The eligible subject population consists of subjects who have been&#xD;
      diagnosed with locally advanced or metastatic melanoma that is refractory to standard therapy&#xD;
      or for which no curative standard therapy exists.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Expansion: Determine the maximum tolerated dose based on dose limiting toxicity of TKI258</measure>
    <time_frame>end of dose escalation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Expansion: Determine the plasma and whole blood pharmacokinetics of orally administered TKI258</measure>
    <time_frame>PK run-in days 1 &amp; 2, cycle 1 days 1, 8, 15, 16, 28, cycle 2 day 15, cycle 2+ day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Escalation: Assess tumor response according to RECIST as measured by response rate and lack of early progressive disease (&lt;=2 months)</measure>
    <time_frame>every 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the safety profile of TKI258 in this patient population</measure>
    <time_frame>PK run in day 1 &amp; 2, cycle 1 day 8, 15, 28, cycle 2+ day 15 &amp; 28, end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effect of TKI258 on biomarkers in the blood</measure>
    <time_frame>PK run day 1 &amp; 2, cycle 1 day 2, 15, 28, cycle 2+ day 28, end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess biomarker changes in tumor/nevi biopsies and archival tumor tissues where accessible, pre- and post-treatment</measure>
    <time_frame>baseline, cycle 1 day 15, end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess changes in tumor glucose metabolism/cell viability between pre- and post-treatment using [18F]-FDG-PET</measure>
    <time_frame>baseline, cycle 1 day 15, cycle 2 day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess anti-angiogenic effects of TKI258 using DCE-MRI pre- and post-treatment</measure>
    <time_frame>baseline, cycle 1 day 2 and cycle 2 day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>TKI258</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TKI258</intervention_name>
    <arm_group_label>TKI258</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of locally advanced or metastatic melanoma (American Joint&#xD;
             Committee on Cancer [AJCC] stage IIIB, IIIC or IV) that is refractory to standard&#xD;
             therapy or for which no curative standard therapy exists.&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Must be eighteen years of age or older&#xD;
&#xD;
          -  Must meet baseline laboratory requirements&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Adults of reproductive potential must agree to use effective contraception or be&#xD;
             sterile&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent therapy with any other investigational agent&#xD;
&#xD;
          -  Uncontrolled central nervous system metastases&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiac disease&#xD;
&#xD;
          -  Received&#xD;
&#xD;
               -  chemotherapy, targeted therapy or monoclonal antibody therapy ≤4 weeks&#xD;
&#xD;
               -  biological therapy or immunotherapy (therapeutic or diagnostic) ≤2 weeks&#xD;
&#xD;
               -  an investigational agent (therapeutic or diagnostic) ≤4 weeks prior to starting&#xD;
                  study drug or has not recovered from side effects of such therapy&#xD;
&#xD;
          -  Received any hematopoietic colony-stimulating factor (e.g., G-CSF, GM-CSF) ≤ 2 weeks&#xD;
             prior to starting study drug. Erythropoietin is allowed.&#xD;
&#xD;
          -  Has undergone major surgery ≤ 2 weeks prior to starting study drug or has not&#xD;
             recovered from side effects of such surgery.&#xD;
&#xD;
          -  Malabsorption syndrome or uncontrolled gastrointestinal symptoms such as nausea,&#xD;
             diarrhea, vomiting&#xD;
&#xD;
          -  Pregnant or breast feeding women&#xD;
&#xD;
          -  History of another primary malignancy that is currently clinically significant or&#xD;
             currently requires active intervention.&#xD;
&#xD;
          -  Chronic anticoagulation therapy with full strength aspirin, Coumadin, or heparin.&#xD;
&#xD;
          -  History of thromboembolic or cerebrovascular events within the last 12 months.&#xD;
&#xD;
          -  History of rectal bleeding, bloody vomit, or spitting up blood within the last 3&#xD;
             months.&#xD;
&#xD;
          -  Known diagnosis of HIV infection (HIV testing is not mandatory)&#xD;
&#xD;
          -  Use of ketoconazole, erythromycin, carbamazepine, phenobarbital, phenytoin, rifampin,&#xD;
             St. John's wort and quinidine is prohibited.&#xD;
&#xD;
          -  Other severe, acute, or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or&#xD;
             study-drug administration or may interfere with the interpretation of study results&#xD;
             and, in the judgment of the investigator, make the patient inappropriate for this&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4202</url>
    <description>Results for (Study ID) from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>March 14, 2006</study_first_submitted>
  <study_first_submitted_qc>March 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2006</study_first_posted>
  <disposition_first_submitted>February 9, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>February 9, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 12, 2013</disposition_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally Advanced or Metastatic Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

